DiaSorin S.p.A. Logo

DiaSorin S.p.A.

DIA.MI

(2.2)
Stock Price

104,20 EUR

-7.49% ROA

12.07% ROE

31.94x PER

Market Cap.

4.954.301.561,00 EUR

0% DER

1.22% Yield

12.97% NPM

DiaSorin S.p.A. Stock Analysis

DiaSorin S.p.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

DiaSorin S.p.A. Fundamental Stock Analysis
# Analysis Rating
1 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

2 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

4 ROE

ROE in an average range (12.11%) suggests satisfactory profitability and decent utilization of shareholders' equity.

5 Dividend Growth

The company's dividend growth has been consistently strong over the past three years, with annual increases that demonstrate its commitment to rewarding shareholders.

6 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (623) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 PBV

The stock's elevated P/BV ratio (3.16x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

8 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

10 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

11 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

DiaSorin S.p.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

DiaSorin S.p.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

DiaSorin S.p.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

DiaSorin S.p.A. Revenue
Year Revenue Growth
2003 134.818.000
2004 147.336.000 8.5%
2005 165.339.000 10.89%
2006 179.756.000 8.02%
2007 202.324.000 11.15%
2008 244.612.000 17.29%
2009 304.129.000 19.57%
2010 404.547.000 24.82%
2011 440.003.000 8.06%
2012 433.763.000 -1.44%
2013 434.849.000 0.25%
2014 443.770.000 2.01%
2015 499.181.000 11.1%
2016 569.312.000 12.32%
2017 637.487.000 10.69%
2018 669.197.000 4.74%
2019 706.319.000 5.26%
2020 881.305.000 19.86%
2021 1.237.654.000 28.79%
2022 1.361.138.000 9.07%
2023 1.080.000.000 -26.03%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

DiaSorin S.p.A. Research and Development Expenses
Year Research and Development Expenses Growth
2003 0
2004 0 0%
2005 0 0%
2006 9.161.000 100%
2007 11.151.000 17.85%
2008 13.835.000 19.4%
2009 16.074.000 13.93%
2010 19.332.000 16.85%
2011 21.481.000 10%
2012 23.393.000 8.17%
2013 23.947.000 2.31%
2014 24.994.000 4.19%
2015 26.158.000 4.45%
2016 37.718.000 30.65%
2017 43.627.000 13.54%
2018 45.082.000 3.23%
2019 47.948.000 5.98%
2020 50.800.000 5.61%
2021 70.091.000 27.52%
2022 96.904.000 27.67%
2023 88.000.000 -10.12%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

DiaSorin S.p.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 0
2004 0 0%
2005 0 0%
2006 20.262.000 100%
2007 24.675.000 17.88%
2008 27.111.000 8.99%
2009 32.384.000 16.28%
2010 41.702.000 22.34%
2011 45.938.000 9.22%
2012 48.181.000 4.66%
2013 49.676.000 3.01%
2014 50.578.000 1.78%
2015 55.494.000 8.86%
2016 60.039.000 7.57%
2017 64.689.000 7.19%
2018 67.216.000 3.76%
2019 69.591.000 3.41%
2020 64.099.000 -8.57%
2021 93.270.000 31.28%
2022 114.687.000 18.67%
2023 120.000.000 4.43%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

DiaSorin S.p.A. EBITDA
Year EBITDA Growth
2003 24.949.000
2004 30.232.000 17.47%
2005 39.380.000 23.23%
2006 54.489.000 27.73%
2007 60.012.000 9.2%
2008 85.618.000 29.91%
2009 122.640.000 30.19%
2010 167.112.000 26.61%
2011 190.020.000 12.06%
2012 171.785.000 -10.62%
2013 161.577.000 -6.32%
2014 164.420.000 1.73%
2015 186.945.000 12.05%
2016 221.391.000 15.56%
2017 248.526.000 10.92%
2018 261.456.000 4.95%
2019 283.986.000 7.93%
2020 391.672.000 27.49%
2021 539.204.000 27.36%
2022 534.198.000 -0.94%
2023 232.000.000 -130.26%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

DiaSorin S.p.A. Gross Profit
Year Gross Profit Growth
2003 67.415.000
2004 73.947.000 8.83%
2005 166.249.000 55.52%
2006 110.089.000 -51.01%
2007 128.077.000 14.04%
2008 160.602.000 20.25%
2009 213.645.000 24.83%
2010 284.735.000 24.97%
2011 313.858.000 9.28%
2012 297.343.000 -5.55%
2013 299.662.000 0.77%
2014 298.738.000 -0.31%
2015 341.897.000 12.62%
2016 389.152.000 12.14%
2017 431.896.000 9.9%
2018 455.769.000 5.24%
2019 488.691.000 6.74%
2020 602.905.000 18.94%
2021 824.771.000 26.9%
2022 900.613.000 8.42%
2023 672.000.000 -34.02%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

DiaSorin S.p.A. Net Profit
Year Net Profit Growth
2003 870.000
2004 3.623.000 75.99%
2005 4.678.000 22.55%
2006 22.294.000 79.02%
2007 25.219.000 11.6%
2008 37.459.000 32.68%
2009 70.047.000 46.52%
2010 90.418.000 22.53%
2011 99.607.000 9.23%
2012 87.396.000 -13.97%
2013 83.028.000 -5.26%
2014 84.074.000 1.24%
2015 100.420.000 16.28%
2016 112.383.000 10.64%
2017 139.878.000 19.66%
2018 158.128.000 11.54%
2019 175.735.000 10.02%
2020 247.871.000 29.1%
2021 310.968.000 20.29%
2022 240.907.000 -29.08%
2023 100.000.000 -140.91%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

DiaSorin S.p.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 1 0%
2009 1 100%
2010 2 0%
2011 2 0%
2012 2 0%
2013 2 0%
2014 2 0%
2015 2 0%
2016 2 50%
2017 3 0%
2018 3 0%
2019 3 33.33%
2020 5 25%
2021 5 20%
2022 4 -25%
2023 2 -300%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

DiaSorin S.p.A. Free Cashflow
Year Free Cashflow Growth
2003 -48.533.000
2004 15.050.000 422.48%
2005 9.560.000 -57.43%
2006 16.207.000 41.01%
2007 13.802.000 -17.43%
2008 28.660.000 51.84%
2009 36.683.000 21.87%
2010 67.410.000 45.58%
2011 79.645.000 15.36%
2012 77.732.000 -2.46%
2013 75.620.000 -2.79%
2014 89.131.000 15.16%
2015 106.401.000 16.23%
2016 128.171.000 16.99%
2017 124.958.000 -2.57%
2018 157.092.000 20.46%
2019 176.880.000 11.19%
2020 229.737.000 23.01%
2021 283.291.000 18.9%
2022 275.655.000 -2.77%
2023 80.000.000 -244.57%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

DiaSorin S.p.A. Operating Cashflow
Year Operating Cashflow Growth
2003 12.954.000
2004 24.460.000 47.04%
2005 21.132.000 -15.75%
2006 33.976.000 37.8%
2007 30.348.000 -11.95%
2008 47.779.000 36.48%
2009 64.219.000 25.6%
2010 95.791.000 32.96%
2011 108.578.000 11.78%
2012 110.582.000 1.81%
2013 107.717.000 -2.66%
2014 119.847.000 10.12%
2015 138.449.000 13.44%
2016 165.597.000 16.39%
2017 167.440.000 1.1%
2018 209.879.000 20.22%
2019 232.670.000 9.8%
2020 304.562.000 23.61%
2021 400.664.000 23.99%
2022 389.341.000 -2.91%
2023 80.000.000 -386.68%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

DiaSorin S.p.A. Capital Expenditure
Year Capital Expenditure Growth
2003 61.487.000
2004 9.410.000 -553.42%
2005 11.572.000 18.68%
2006 17.769.000 34.88%
2007 16.546.000 -7.39%
2008 19.119.000 13.46%
2009 27.536.000 30.57%
2010 28.381.000 2.98%
2011 28.933.000 1.91%
2012 32.850.000 11.92%
2013 32.097.000 -2.35%
2014 30.716.000 -4.5%
2015 32.048.000 4.16%
2016 37.426.000 14.37%
2017 42.482.000 11.9%
2018 52.787.000 19.52%
2019 55.790.000 5.38%
2020 74.825.000 25.44%
2021 117.373.000 36.25%
2022 113.686.000 -3.24%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

DiaSorin S.p.A. Equity
Year Equity Growth
2003 54.134.000
2004 55.207.000 1.94%
2005 6.745.000 -718.49%
2006 87.737.000 92.31%
2007 120.273.000 27.05%
2008 154.147.000 21.98%
2009 217.855.000 29.24%
2010 315.936.000 31.04%
2011 351.178.000 10.04%
2012 367.587.000 4.46%
2013 413.953.000 11.2%
2014 483.369.000 14.36%
2015 586.814.000 17.63%
2016 662.817.000 11.47%
2017 741.417.000 10.6%
2018 704.735.000 -5.21%
2019 848.623.000 16.96%
2020 956.319.000 11.26%
2021 1.367.939.000 30.09%
2022 1.519.750.000 9.99%
2023 1.553.239.000 2.16%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

DiaSorin S.p.A. Assets
Year Assets Growth
2003 187.212.000
2004 180.165.000 -3.91%
2005 179.283.000 -0.49%
2006 194.081.000 7.62%
2007 208.328.000 6.84%
2008 264.717.000 21.3%
2009 336.907.000 21.43%
2010 447.627.000 24.73%
2011 474.201.000 5.6%
2012 525.020.000 9.68%
2013 526.616.000 0.3%
2014 605.691.000 13.06%
2015 707.906.000 14.44%
2016 868.618.000 18.5%
2017 945.723.000 8.15%
2018 905.940.000 -4.39%
2019 1.063.552.000 14.82%
2020 1.246.446.000 14.67%
2021 3.231.152.000 61.42%
2022 3.408.082.000 5.19%
2023 0 0%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

DiaSorin S.p.A. Liabilities
Year Liabilities Growth
2003 134.628.000
2004 124.958.000 -7.74%
2005 172.538.000 27.58%
2006 106.344.000 -62.25%
2007 88.055.000 -20.77%
2008 110.570.000 20.36%
2009 119.052.000 7.12%
2010 131.691.000 9.6%
2011 123.023.000 -7.05%
2012 156.939.000 21.61%
2013 112.481.000 -39.52%
2014 122.118.000 7.89%
2015 120.748.000 -1.13%
2016 205.233.000 41.17%
2017 203.768.000 -0.72%
2018 201.205.000 -1.27%
2019 214.929.000 6.39%
2020 290.127.000 25.92%
2021 1.863.213.000 84.43%
2022 1.888.332.000 1.33%
2023 0 0%

DiaSorin S.p.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
22.43
Net Income per Share
2.81
Price to Earning Ratio
31.94x
Price To Sales Ratio
4.15x
POCF Ratio
15.56
PFCF Ratio
16.1
Price to Book Ratio
3.08
EV to Sales
4.15
EV Over EBITDA
17.71
EV to Operating CashFlow
16.1
EV to FreeCashFlow
16.1
Earnings Yield
0.03
FreeCashFlow Yield
0.06
Market Cap
4,95 Bil.
Enterprise Value
4,95 Bil.
Graham Number
42.94
Graham NetNet
0

Income Statement Metrics

Net Income per Share
2.81
Income Quality
3.86
ROE
0.1
Return On Assets
0.06
Return On Capital Employed
0.1
Net Income per EBT
0.79
EBT Per Ebit
0.79
Ebit per Revenue
0.21
Effective Tax Rate
0.21

Margins

Sales, General, & Administrative to Revenue
0.1
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.64
Operating Profit Margin
0.21
Pretax Profit Margin
0.16
Net Profit Margin
0.13

Dividends

Dividend Yield
0.01
Dividend Yield %
1.22
Payout Ratio
0
Dividend Per Share
1.1

Operating Metrics

Operating Cashflow per Share
5.77
Free CashFlow per Share
5.77
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.13
Return on Tangible Assets
-0.07
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
29,15
Tangible Book Value per Share
0
Shareholders Equity per Share
29.15
Interest Debt per Share
0.72
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0
Current Ratio
0
Tangible Asset Value
-2,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

DiaSorin S.p.A. Dividends
Year Dividends Growth
2008 0
2009 0 0%
2010 0 0%
2011 1 0%
2012 1 100%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 3 100%
2019 1 0%
2020 2 100%
2021 1 0%
2022 1 0%
2023 1 0%

DiaSorin S.p.A. Profile

About DiaSorin S.p.A.

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

CEO
Mr. Carlo Rosa
Employee
3.344
Address
Via Crescentino snc
Saluggia, 13040

DiaSorin S.p.A. Executives & BODs

DiaSorin S.p.A. Executives & BODs
# Name Age
1 Mr. Fabrizio Piercarlo Bonelli
Corporate Vice President & Chief Technology Officer
70
2 Mr. Ulisse Spada
Corporate Vice President, Head of the Legal Department, Secretary & General Counsel
70
3 Mr. Angelo Rago
President of Luminex Corporation
70
4 Dr. Riccardo Fava
Corporate Vice President of Communication & Investor Relations
70
5 Mr. Stefano Ronchi
Senior Corporate Vice President of Human Resources
70
6 Mr. Piergiorgio Pedron
Senior Corporate Vice President, Chief Financial Officer & Corporate Accounting Documents Officer
70
7 Dr. Chen Menachem Even
Chief Commercial Officer, Senior Corporate Vice President of Commercial Operations & Executive Director
70
8 Mr. Carlo Rosa
Chief Executive Officer, GM & Executive Director
70
9 Mr. Ugo Gay
Chief Executive Officer of DiaSorin Italia S.p.A.
70

DiaSorin S.p.A. Competitors